Ashok Patel
Toms River, NJNPI 1093809576
Payments from drug & device makers
Across 905 payments — averaging $12,663 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bioxcel Therapeutics, Inc.$4.2M
- AbbVie$1.8M
- Eli Lilly$1.6M
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1.1M
- Eisai Inc.$859K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$673K
- plus $1.2M from 22 others
Across 52 payments — averaging $824.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$36K
- Acadia Pharmaceuticals Inc$3K
- AbbVie$3K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
What the payments were for
- Consulting fees$14,81623%
- Speaking & faculty fees$40,63764%
- Travel & lodging$3,7776%
- Food & beverage$3,8636%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bioxcel Therapeutics, Inc. | 15 | $4,161,416 |
| AbbVie(2 entities) | 350 | $1,822,963 |
| Eli Lilly | 43 | $1,627,532 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 18 | $1,124,986 |
| Eisai Inc. | 118 | $859,050 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 89 | $673,405 |
| Boehringer Ingelheim | 15 | $583,842 |
| Acadia Pharmaceuticals Inc | 48 | $247,644 |
| Amgen | 12 | $108,698 |
| Avanir Pharmaceuticals, Inc. | 27 | $76,181 |
| Otsuka America Pharmaceutical, Inc. | 65 | $44,237 |
| E.r. Squibb & Sons, L.L.C. | 3 | $41,544 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $36,733 |
| Biohaven Pharmaceuticals, Inc. | 3 | $24,466 |
| Genentech, Inc. | 1 | $17,736 |
| Boehringer Ingelheim International GmbH | 41 | $8,884 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $205 |
| Vanda Pharmaceuticals Inc. | 6 | $79 |
| Merck | 2 | $76 |
| Neurocrine Biosciences, Inc. | 5 | $71 |
| Lilly USA, LLC | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 5 | $64 |
| Johnson & Johnson | 3 | $42 |
| Jazz Pharmaceuticals Inc. | 3 | $39 |
| Shire North American Group Inc | 2 | $29 |
| Lundbeck LLC | 2 | $26 |
| UCB, Inc. | 1 | $15 |
| Life Molecular Imaging Ltd | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 13 | $22,847 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $1,336 |
| Bupropion XlBupropion Hcl | 17 | $598 |
| Trazodone Hcl | 14 | $532 |
| Sertraline Hcl | 19 | $344 |
| Donepezil Hcl | 27 | $306 |
| Memantine Hcl | 15 | $292 |
| Lorazepam | 41 | $278 |
| Mirtazapine | 35 | $203 |
| Alprazolam | 22 | $178 |
| Escitalopram Oxalate | 23 | $74 |
| Bupropion Hcl SrBupropion Hcl | 12 | $33 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $44,237 | $22,84713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.